CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home » NEWS

Oncology NEWS International. Vol. 7 No. 9
 

Long-Term Follow-up Shows Good QOL After Allo Transplant

September 1, 1998

SAN DIEGO--Researchers at the Fred Hutchinson Cancer Research Center, Seattle, have been monitoring the institution’s transplant patients for quality of life (QOL) for more than two decades, Keith Sullivan, MD, of the Department of Medical Oncology, said at the Sixth International Symposium on Recent Advances in Hematopoietic Stem Cell Transplantation, sponsored by the University of California, San Diego.

More than 2,500 Hutchinson transplant patients are actively being followed in several ways, he said.

  • On-site examinations are conducted at the first transplant anniversary and various anniversaries thereafter. The exams include detailed medical, hematologic, and immunologic evaluations.

  • Questionnaires are sent to referring physicians at 6 months and then at each anniversary.

  • Patients are sent a questionnaire each year that asks questions about functional performance, symptoms, and medical complications.

With this system, Dr. Sullivan said, all but 4% to 8% of surviving patients have been contacted for updates within the last 2 years.

While recent studies of former transplant patients have reported that most survivors do relatively well, many of these cross-sectional studies have been limited by such things as a follow-up of less than 5 years, limited scope, and small sample size. Hutchinson researchers have tried to fill in this gap.

Long-Term Survivors

One study, headed by Dr. Nigel Bush, scrutinized the quality of life of long-term transplant survivors. Participants in the study had survived a mean of 10 years since transplantation. Some had their transplant as far back as 18 years ago. Of the 125 patients, 87% had an allogeneic transplant and the rest autologous. One measurement used in the study was a 270-item survey that took patients about 90 minutes to complete.

Overall, the news from this research was quite good. "In general, the severity of complaints was low," Dr. Sullivan observed. "Eighty percent listed their current quality of life as good to excellent, while 5% listed it as poor."

Although there were lingering complaints of such problems as fatigue, sexual dysfunction, and sleep disturbances, most survivors considered these to be of low severity, and 88% said the benefits of transplant outweighed the side effects.

Return to Normal Functioning

In another Hutchinson study, Dr. Karen Syrjala and colleagues prospectively analyzed 67 adults before and after allogeneic transplantation. Physical function was most impaired at 90 days after transplant, and most patients had returned to their normal functioning by 1 year. Two years after transplantation, 68% had returned to full-time work, and only 9% still had not done so by the fourth transplant anniversary.

Before the transplant, 27% of patients complained of depression, while 41% experienced anxiety. These numbers did not change the first year after the transplant. Persons who were single or had experienced family conflict before the cancer were more likely to experience greater emotional distress a year after transplantation. A patient was more likely to bounce back if he or she enjoyed a strong family relationship.

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.






 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
FROM PHYSICIANS PRACTICE
Primary Care Can't Thrive Without Nurse Practitioners
Courtney H. Lyder, ND,  May 17, 2013
With a projected shortfall of primary-care physicians, it's time for alternate solutions to patient care. Nurse practitioners are one logical remedy.
VWhat Physicians Can Learn from the Allscripts EHR Lawsuit
Marisa Torrieri,  May 16, 2013
Lawsuit prompts question: What should physicians do to ensure they end up with a great EHR instead of buyer’s remorse?
Eight Ways ICD-9 Will Still Matter to Medical Practices
Brenda Edwards, CPC,  May 15, 2013
What should your medical practice do with your ICD-9-CM book after October 1, 2014? Keep it.
Seven Ways Technology Can Speed Up Patient Collections
Cheyenne Brinson,  May 15, 2013
Failing to adopt widely available billing and collections technology can cost medical practices big. Here's how to do it right.
Four Reasons Private Medical Practice is Becoming Extinct
Carol Stryker,  May 15, 2013
It’s becoming increasingly difficult for private medical practices to thrive. Here’s what’s driving the trend toward consolidation.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Skin Lesions
  • Colorectal Lesions
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Slide Show: Squamous Cell Carcinoma of the Head and Neck
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • ONS: Understanding Spirituality and How It Can Be Used to Help Patients
  • Colorectal Lesions
  • New AUA Guidelines for Prostate Cancer Screening
  • 50 Shades of Pink—And Why It Helps to Know the Difference
  • Genomics Studies Identify Testicular Cancer Risk Variants
  • Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
  • FDA Approves Erlotinib (Tarceva) as First-Line Lung Cancer Therapy for Certain Patients
Click here to subscribe to our newsletter


CancerNetwork on Facebook


CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy